96 results
8-K
EX-99.1
FGEN
FibroGen Inc
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
treatments for this devastating disease.”
Preliminary safety data showed that pamrevlumab was generally safe and well tolerated. The majority of treatment
8-K
hhr v95acjv
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
iew5 8pytnc1o
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
j7i0mpuenuvxqa7u
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
DEFA14A
gtf8i3v22iiambz4zx
31 May 23
Additional proxy soliciting materials
9:00am
8-K
ioow3
1 May 23
Entry into a Material Definitive Agreement
4:48pm
S-3ASR
ujl8paf
8 Aug 22
Automatic shelf registration
5:12pm